Global Polycystic Ovary Syndrome Market Set to Reach USD 12.6 Billion by 2035, with a 7.3% CAGR

The global Polycystic Ovary Syndrome market is estimated at USD 5.82 billion in 2024 and is projected to grow at a CAGR of 7.3% during the forecast period 2025-2035. The Polycystic Ovary Syndrome (PCOS) market range covers several medicinal treatments that can be used in either the management of symptoms or complications of the hormonal disorder. This affects several body systems and brings forth problems such as irregular menstrual cycles and hormonal imbalances, among others. These products include pharmaceuticals, fertility treatments, and lifestyle management products. Continual research and development in new treatments and diagnostic strategies will continue to advance improved patient results. Improved healthcare technology combined with a greater understanding around the world of the prevalence of PCOS will just continue growing and fill an enormous unmet need in healthcare.

To explore in-depth analysis in this report - Request Free Sample Report

What are the Top Factors Driving Growth in the Polycystic Ovary Syndrome Market?

Growing Incidence of Polycystic Ovary Syndrome Diagnoses Worldwide

Polycystic ovary syndrome (PCOS) is a major women's health issue increasingly recognized today. The Endocrine Society states that it affects about 7% to 10% of women of childbearing age in the United States and leads to a tremendous rate of infertility. This increased prevalence has thus increased the level of awareness and self-diagnosis, as women have been visiting physicians regarding complaints such as irregular menstrual cycles, difficulty in conceiving, and secondary metabolic conditions. Approximately 5 to 6 million women in the United States, screening and awareness about the disorder are thus of paramount importance in clinical practice with proper diagnosis and management of the condition.

Browse key industry insights spread across 230 pages with 120+ Market data tables and figures & charts from the report on the “Polycystic Ovary Syndrome Market By Treatment Type (Medication {Oral Contraceptives, Anti-Androgens, Insulin-Sensitizing Agents, Gonadotropins, and Fertility Drugs}, Surgery {Ovarian wedge resection, Laparoscopic ovarian drilling, and Other surgeries}, and Others), By Drug Class (Hormonal Drugs, Anti-diabetics, Anti-obesity Drugs, and Anti-depressants), By Diagnosis (Ultrasound, Blood Tests, Physical Examination, and Pelvic Exam), and By End-User (Hospitals, Fertility Clinics, Ambulatory Surgical Centers, and Diagnostic Centers) Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035”

Download an Exclusive Sample of the Report: https://www.metatechinsights.com/request-sample/1058

Technological advancement in diagnostics

It is seen that development in diagnostic technologies advances the growth of the market for PCOS largely. The World Health Organization reports PCOS to affect about 8–13% of women of reproductive age but still points out that up to 70% of these cases remain undiagnosed globally. Recent technological innovations have considerably improved both early detection and diagnostic accuracy of PCOS. Serum biomarkers have indeed provided better and more reliable early diagnoses, especially in asymptomatic or younger women, through anti-Müllerian hormone (AMH). Other hormonal assays for luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone have become more sensitive and accurate. Another component that is crucial to enhancing reproductive outcomes for women with PCOS is improvements in high-resolution 3D transvaginal ultrasounds and color Doppler ultrasound.

What are the significant challenges impacting the Polycystic Ovary Syndrome Market?

Limited Therapeutic Options and Innovation Barriers

PCOS treatment is only on a limited scale and primarily directed toward the control of symptoms instead of addressing the main causes. Treatment with birth control pills and metformin, originally given to people who suffer from other diseases, cannot work on correcting insulin resistance or hormonal imbalance. According to NIH reports, 35% to 80% of women have insulin resistance while inflicted with PCOS. There is no FDA-approved drug for PCOS yet, and innovation in developing targeted therapies is very slow. This is another challenging step toward proper management and calls for the use of personalized approaches to treatment.

What are the attractive investment opportunities that can drive industry growth?

Development of targeted and personalized therapies

A considerable opportunity for improving the effectiveness of treatment and quality of care exists with the development of targeted and patient-specific therapies for PCOS. According to new data, approximately 70% of women affected by PCOS worldwide remain undiagnosed, mainly for a lack of specific customized treatment options, which are documented by the World Health Organization. One of the most important gaps in the profile of therapies applied here is not being responsive to individual specific hormonal and metabolic profiles of the treated patient. Personalized strategies, including pharmacogenomics, make it possible to have treatments targeted at the specific genetic patterns of the individual increase drug efficacy, and minimize side effects. Targeted therapies focused on overcoming insulin resistance and hormonal imbalances will likely result in much-needed relief for many women, suggests NIH researchers. Therefore, the progress of such specific therapies would promote better handling of PCOS by the healthcare industry, thus fostering quality of life for millions of women in the world.

Read more about the report: https://www.metatechinsights.com/industry-insights/polycystic-ovary-syndrome-market-1058  

North America Plays a Crucial Role in the Polycystic Ovary Syndrome Market Landscape

High prevalence of the disorder in North America is an extremely common endocrine-metabolic abnormality, and an estimated 7% to 10% of women of reproductive age are influenced by this disorder. The global prevalence of PCOS is about 4% to 21% according to the nature of diagnostic criteria used. The region is well facilitated with advanced infrastructure related to healthcare and is becoming more aware of the disorder. Due to these factors, more cases of patients are being reported, and appropriate treatment-seeking behavior is being observed among women in the affected community. Innovation in therapeutic options is being driven by the presence of major pharmaceutical companies and ongoing research initiatives.

In addition, the concept of personalized medicine and targeted therapies is increasingly evolving and impacting the market, thereby considering individual profiles of hormonal and metabolic features. Government support and funding are crucial, particularly from the NIH, with its investment of about $30 billion in annual biomedical research. This trend, however, is also supplemented by digital health tool advancement and telemedicine, thus enhancing access to care and possibly timely interventions. The North American PCOS market seems promising regarding awareness, research, and a focus on individualized treatment strategies with time.

Asia Pacific Regional Landscape of the PCOS Market, China at the Forefront

The increase in the demand in the PCOS market is being observed along the Asia Pacific region, due to growing awareness of the disease and its related health effects. In 2020, a case-control study looked at the 826 participants who were diagnosed with PCOS and found the weighted prevalence among women of reproductive ages was at 7.8% (95% CI: 7.0%, 9.0%), thus estimated at 24 million in China. Fast urbanization and lifestyle changes, accompanied by growing obesity prevalence, make patients with PCOS increase users of healthcare services.

Innovative targeted therapies are coming both from emerging pharmaceutical companies and research initiatives. Meanwhile, efforts of the government, as well as specific programs to advance women's health, are improving access to care and treatment. Digital health solutions, such as telemedicine, better aid in timely diagnosis and management. PCOS Market in Asia Pacific is expected to rise at a high pace with strengthened awareness, better health care infrastructure, and emphasis on customized treatment strategies.

Competitive Landscape

The key players in the PCOS market are Teva Pharmaceuticals Industries Ltd., Bayer AG, Abbott Laboratories, Merck & Co., Inc., and Bristol-Myers Squibb. Teva Pharmaceuticals is expanding its offerings of generic and specialty drugs to treat various PCOS-related symptoms. Bayer AG is using the research experience of women's health to develop therapy products based on hormonal imbalances. It has recently collaborated with research centers to launch this line of targeted therapies. Abbott Laboratories builds its diagnostics capabilities by investing in technologies aimed at improving the detection of PCOS and by pursuing partnerships to expand its therapeutic portfolio. Merck & Co., Inc. advances the research for approaches that shall constitute the backbone of personalized medicine in PCOS, including new therapies. Finally, Bristol-Myers Squibb is active in forging mergers and collaborations to strengthen its women's health pipeline, notably with innovative therapy for managing PCOS symptoms. Together, these efforts will put these companies at the forefront of PCOS innovation, regarding extending the range of treatment options and outcomes for the patients.

Recent Developments

• In March 2023, Ferring Pharmaceuticals started a new clinical trial of its new fertility treatment, Rekovelle®, designed only for women with PCOS. The clinical trial will provide a safer alternative for women undergoing ovulation induction with more exact dosing and improved results in ART.

• In June 2022, Bayer announced the launch of its brand-new Research and Innovation Center at Kendall Square in the United States, increasing the company's presence in one of the most cutting-edge centers for pharmaceutical research and development.

Report Coverage:

By Treatment Type

• Medication
  • Oral Contraceptives
  • Anti-Androgens
  • Insulin-Sensitizing Agents
  • Gonadotrophins
  • Fertility drugs
• Surgery
  • Ovarian wedge resection
  • Laparoscopic ovarian drilling
  • Other surgeries
• Others

By Drug class

• Hormonal Drugs
• Anti-diabetics
• Anti-obesity Drugs
• Anti-depressants

By Diagnosis

• Ultrasound
• Blood Tests
• Physical Examination
• Pelvic Exams

By End-user

• Hospitals
•  Fertility Clinics
• Ambulatory Surgical Centers
• Diagnostic centers

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Teva Pharmaceuticals Industries Ltd.
• Bayer AG
• Abbott Laboratories
• Merck& Co., Inc.
• Bristol-Myers Squibb
• Ferring Pharmaceuticals
• Sanofi S.A.
• AstraZeneca
• Novartis AG
• GlaxoSmithKline plc (GSK)
• Pfizer Inc.
• Takeda Pharmaceutical Company Limites
• Johnson & Johnson
• Sun Pharmaceutical Industries Ltd.
• Ipsen Pharma